Press releaseGlobe Newswire
Pluri
PLUR · NASDAQ
$0.90+$0.0499 (+5.87%)TodayMarket closed ·
Prev close $0.8501
Latest news
- Press releaseGlobe Newswire
Pluri's Ever After Foods Expands Cultivated-Protein Platform Through Fishway Acquisition and Strategic Investment
- Press releaseGlobe Newswire
Ever After Foods Acquires Fishway to Expand Integrated Food Production Technology Platform
- News
Pluri Unit Cellav Health And Aesthetics Completes Cosmetic Regulatory Registration And Notification In The UK, Supporting Commercial Launch Of Regenativo+
- Press releaseGlobe Newswire
Pluri Advances Commercial Expansion Through Its Subsidiary Cellav, Completing Regulatory Registration in the UK
- Press releaseGlobe Newswire
Pluri Chairman Alejandro Weinstein’s Cumulative Investment Exceeds $17 Million, Ownership Surpasses 30%
- Press releaseGlobe Newswire
Pluri Advances Toward U.S. Commercial Launch Through Its Subsidiary Cellav, Following Completion of Regenerative Aesthetic Products Listing
- Press releaseGlobe Newswire
Pluri Secures Additional Investment from Chairman Alejandro Weinstein at 30% Premium to Market in a Private Placement
- Press releaseGlobe Newswire
Pluri Secures Global IP Position with China Patent Grant for Large-Scale Immune Cell Expansion, Complementing Prior U.S. Patent
- Press releaseGlobe Newswire
Pluri Successfully Completes First Phase of Resbiomed Program for Placenta-Derived Collagen-Rich Biomaterials
- Press releaseGlobe Newswire
Pluri and Subsidiaries Earn Multiple Industry Honors, Named as Overall BioAgriculture Company of the Year
- News
12 Health Care Stocks Moving In Monday's Intraday Session
- Press releasePRNewswire
BrainStorm Secures Key Manufacturing Partnership with Minaris for Upcoming NurOwn® Phase 3b ALS Clinical Trials
- Press releasePRNewswire
DarioHealth Announces CFO Transition
- Press releasePRNewswire
BrainStorm Cell Therapeutics and Pluri Partner to Support NurOwn® Phase 3b Trial Manufacturing
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.